… is an essential part in the surgical management of invasive vulvar cancer stage I-II. … novel
methylation biomarkers for cervical cancers. We initially isolated 708 genes down-regulated in …

… in EPCs are a potential biomarker of sorafenib efficacy 120 . … a selective cyclooxygenase-2
(COX2) inhibitor (celecoxib) … in phase I/II clinical testing in patients with breast cancer 165 . …

… on cyclooxygenase-2 inhibitor enzymes such as Celecoxib have … the Celecoxib course has
been studied for patients with cervical … cancer: evaluation of drug-specific biomarkers. Journal …

… tumor biology thereby allowing improved patient counseling. Owing to controversial results
in various studies, however, most biomarkers … factor (VEGF), cyclooxygenase 2 (COX-2), and …

… Cyclooxygenase-2 inhibitor studies in animal models have thrown light on its role in … %,
respectively, in cervical cancer patients receiving chemo-radiotherapy treated with celecoxib [20] …

… of the microbiome and the tumor microenvironment [9]. … skin cancer, melanoma in situ,
Stage I cervical cancer, or … III colon cancer patients to a 3 year intervention of celecoxib or …

… distant metastases in cervical cancer. Recent phase I-II trial using celecoxib in patients with
carcinoma of the cervix was published. Yet there is no definite positive outcome with COX-2 …

… evaluation of durvalumab is taking place in the phase I/II … following BCG treatment, and
cyclooxygenase-2 (COX2) has … clinical trials involving systemic blockade of COX2 (oral celecoxib)…

… ), are able to interfere with tumor microenvironment by reducing cell … of the STAT3 pathway
in cervical cancer. Together, the … FAP patients that used a specific COX-2 inhibitor, celecoxib, …

… M2 phenotype, contributing to cervical carcinoma tumor angiogenesis (34). In colorectal … -2
inhibitor celecoxib on tumor characteristics in patients with stage I/II primary breast cancer (70)…